An electroencephalographic signature predicts antidepressant response in major depression.

Autor: Wu W; School of Automation Science and Engineering, South China University of Technology, Guangzhou, Guangdong, China.; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Zhang Y; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Jiang J; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Lucas MV; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Fonzo GA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Rolle CE; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Cooper C; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.; O'Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA., Chin-Fatt C; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.; O'Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA., Krepel N; Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands.; Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands., Cornelssen CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Wright R; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Toll RT; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Trivedi HM; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Monuszko K; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Caudle TL; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Sarhadi K; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA., Jha MK; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA., Trombello JM; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.; O'Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA., Deckersbach T; Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA., Adams P; New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA., McGrath PJ; New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA., Weissman MM; New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA., Fava M; Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA., Pizzagalli DA; Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA., Arns M; Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands.; Department of Experimental Psychology, Utrecht University, Utrecht, the Netherlands.; neuroCare Group Netherlands, Nijmegen, the Netherlands., Trivedi MH; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.; O'Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA., Etkin A; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. amitetkin@stanford.edu.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA. amitetkin@stanford.edu.; Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC), Palo Alto, CA, USA. amitetkin@stanford.edu.
Jazyk: angličtina
Zdroj: Nature biotechnology [Nat Biotechnol] 2020 Apr; Vol. 38 (4), pp. 439-447. Date of Electronic Publication: 2020 Feb 10.
DOI: 10.1038/s41587-019-0397-3
Abstrakt: Antidepressants are widely prescribed, but their efficacy relative to placebo is modest, in part because the clinical diagnosis of major depression encompasses biologically heterogeneous conditions. Here, we sought to identify a neurobiological signature of response to antidepressant treatment as compared to placebo. We designed a latent-space machine-learning algorithm tailored for resting-state electroencephalography (EEG) and applied it to data from the largest imaging-coupled, placebo-controlled antidepressant study (n = 309). Symptom improvement was robustly predicted in a manner both specific for the antidepressant sertraline (versus placebo) and generalizable across different study sites and EEG equipment. This sertraline-predictive EEG signature generalized to two depression samples, wherein it reflected general antidepressant medication responsivity and related differentially to a repetitive transcranial magnetic stimulation treatment outcome. Furthermore, we found that the sertraline resting-state EEG signature indexed prefrontal neural responsivity, as measured by concurrent transcranial magnetic stimulation and EEG. Our findings advance the neurobiological understanding of antidepressant treatment through an EEG-tailored computational model and provide a clinical avenue for personalized treatment of depression.
Databáze: MEDLINE